Uncategorized
Novartis to in-license potential dry eye treatment
Novartis will in-license its recombinant human lubricin ECF843 for ophthalmic indications, the company announced in a press release. Developed by Lubris LLC, ECF843 is thought to compensate for lubricin protein deficiency in patients with dry eye by reducing friction, restoring tear film function and relieving signs and symptoms of dry eye.